exv10w21



 




Exhibit 10.21


 


THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE
ACT OR UNLESS SUCH TRANSACTION IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES
LAWS.




NORTHWEST BIOTHERAPEUTICS, INC.




WARRANT




			
	 	 	 
	No.___BW-___
	 	___, 2007





This Certifies That, for value received and subject to the provisions set forth in this
amended and restated warrant (this “Warrant”), Toucan Partners, LLC, with its principal
office at 7600 Wisconsin Avenue, Suite 700, Bethesda, MD 20814, and/or its assigns (collectively,
the “Holder”), is entitled to subscribe for and purchase from Northwest Biotherapeutics,
Inc., a Delaware corporation, with its principal office at 17801 120th Avenue NE,
Suite 101, Bothell, Washington 98011 (the “Company”), such number of Exercise Shares as provided
herein at the Exercise Price (each subject to adjustment as provided herein). This Warrant is
amended and restated in its entirety as of April ___, 2007 (the “Restatement Date”), and amends,
restates and supersedes in full that certain Warrant No. BW-___dated as of ___,, 200___issued by
the Company in favor of the Holder (the “Original Warrant”) issued pursuant to the terms of the
Amended and Restated Recapitalization Agreement, dated July 30, 2004, as amended on October 22,
2004, November 10, 2004, December 27, 2004, January 26, 2005, April 12, 2005, May 13, 2005, June
16, 2005, July 26, 2005, September 7, 2005 and November 14, 2005, by and among the Company and
Toucan Capital Fund II, L.P. (the “Recapitalization Agreement”).




     1. Definitions. Capitalized terms used but not defined herein shall have the meanings
set forth in the Recapitalization Agreement or Related Recapitalization Document, as applicable. As
used herein, the following terms shall have the following respective meanings:



          (a) “Capital Stock” shall mean the securities for which this Warrant is exercisable as
provided in Section 2.2 hereof.




          (b) “Exercise Period” shall mean the period commencing on the date of issuance of this Warrant
and ending seven (7) years after the date of issuance of this Warrant.




          (c) “Exercise Price” of this Warrant shall be equal to the conversion price that would apply
under Section 12.2 of the Note if Holder elected to convert any principal and/or accrued interest
under the Note into Capital Stock of the Company, regardless of whether Holder does elect to make
any such conversion.




          (d) “Exercise Share” shall mean each of the shares of Capital Stock for which this
Warrants is exercisable. The warrant coverage shall be equal to one hundred percent
(100%) of the principal and accrued interest on the Note. This Warrant shall be issued by the




 1.









 







Company upon execution of the Note. The number of warrant shares shall be equal to the number of
shares of Capital Stock that would be issuable to Holder, as determined in accordance with Section
12.2 of the Note, if Holder elected to convert the full principal and interest of the Note. For the
avoidance of doubt, the 100% warrant coverage will be effective regardless of whether or not Holder
elects to convert any or all of the principal and/or interest of the Note. This Warrant will be
fully vested and exercisable upon issuance, and will have an exercise period of seven (7) years
from the date of issuance. The number shares of Capital Stock is based on the principal and
accrued interest on that certain ___Amended and Restated Loan Agreement and 10% Promissory
Note (the “Note”) of even date herewith evidencing a loan from Holder in principal amount of
$xxx,xxx.xx that was originally advanced to the Company on ___, 200_.




     2. Exercise of Warrant. The rights represented by this Warrant may be exercised in
whole or in part at any time or times during the Exercise Period, by delivery of the following to
the Company at its address set forth above (or at such other address as it may designate by notice
in writing to the Holder):



          (a) An executed Notice of Exercise in the form attached hereto;




          (b) Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of
indebtedness; and




          (c) This Warrant.




     Upon the exercise of the rights represented by this Warrant, a certificate or certificates for
the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with
the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a
reasonable time after the rights represented by this Warrant shall have been so exercised. In the
event that this Warrant is being exercised for less than all of the then-current number of Exercise
Shares purchasable hereunder, the Company shall, concurrently with the issuance by the Company of
the number of Exercise Shares for which this Warrant is then being exercised, issue a new Warrant
exercisable for the remaining number of Exercise Shares purchasable hereunder.



     The person in whose name any certificate or certificates for Exercise Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on
the date on which this Warrant was surrendered and payment of the Exercise Price was made,
irrespective of the date of delivery of such certificate or certificates, except that, if the date
of such surrender and payment is a date when the stock transfer books of the Company are closed,
such person shall be deemed to have become the holder of such shares at the close of business on
the next succeeding date on which the stock transfer books are open.



     2.1 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market
value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set
forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to
receive shares equal to the value (as determined below) of this Warrant (or the portion thereof
being canceled) by surrender of this Warrant at the principal office of the Company together with



 2.









 







the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder
a number of Exercise Shares computed using the following formula:



	 	 	 	 	 
	X =

	 	Y (A-B)
	 	 
	 

	 	 	 	 
	 

	 	A	 	 






	 	 	 	 	 
	Where

	 	X =  
	 	the number of Exercise Shares to be issued to the Holder
	 
	 	 	 	 
	 

	 	Y =
	 	the number of Exercise Shares purchasable under the Warrant
or, if only a portion of the Warrant is being exercised, that portion of the
Warrant being canceled (at the date of such calculation)
	 
	 	 	 	 
	 

	 	A =
	 	the fair market value of one Exercise Share (at the date of
such calculation)
	 
	 	 	 	 
	 

	 	B =
	 	Exercise Price (as adjusted to the date of such calculation)






     For purposes of the above calculation, the fair market value of one Exercise Share shall be
determined by the Company’s Board of Directors in good faith; provided, however, that in the event
that this Warrant is exercised pursuant to this Section 2.1 in connection with the Company’s
initial public offering of its Common Stock, the fair market value per share shall be the product
of (i) the per share offering price to the public of the Company’s initial public offering, and
(ii) the number of shares of Common Stock into which each Exercise Share is convertible at the time
of such exercise.



     2.2 Securities for Which Warrant is Exercisable. This Warrant shall be exercisable, in whole
or in part, and from time to time, for any Equity Security and/or Debt Security and/or any
combination thereof (collectively “Capital Stock”), in each case that Holder shall designate in
Holder’s sole discretion.



3. Covenants of the Company.




          3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares
that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance,
be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and
charges with respect to the issuance thereof. The Company further covenants and agrees that the
Company will at all times during the Exercise Period, have authorized and reserved, free from
preemptive rights, a sufficient number of shares of the series of equity securities comprising the
Exercise Shares and the Company’s Common Stock to provide for the exercise of the rights
represented by this Warrant and the subsequent conversion of the Exercise Shares. If at any time
during the Exercise Period the number of authorized but unissued shares of such series of the
Company’s Capital Stock shall not be sufficient to permit exercise of this Warrant or the
subsequent conversion of the Exercise Shares, then, in addition to such other remedies as may be
available to Holder, including, without limitation, the exercise of Holder’s right of first refusal
set forth in Section 2.7(f) of the Recapitalization Agreement, the Company will take such corporate
action as shall be necessary to increase its authorized but unissued shares of such series of the
Company’s equity securities or the Company’s Common Stock, as appropriate, to such number of shares
as shall be sufficient for such purposes.




 3.









 








          3.2 Notices of Record Date. In the event of any taking by the Company of a record of the
holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at
least ten (10) days prior to the date specified herein, a notice specifying the date on which any
such record is to be taken for the purpose of such dividend or distribution.




          3.3 No Impairment. The Company shall not, by amendment of its Charter or through a
reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities, or any other voluntary action, omission or agreement, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed by the Company under
and/or in connection with this Warrant, but shall at all times in good faith use best efforts to
assist in carrying out of all the provisions of and/or relating to this Warrant and in taking all
such action as may be necessary or appropriate to protect Holder’s rights, preferences and
privileges under and/or in connection with this Warrant against impairment. The Holder’s rights,
preferences and privileges granted under and/or in connection with this Warrant may not be amended,
modified or waived without the Holder’s prior written consent, and the documentation providing for
such rights, preferences and privileges will specifically provide as such.




          3.4 Registration Rights. The Company agrees that the Underlying Shares (as defined below)
shall be “registrable securities” (or terms of similar impact) under any agreement executed by the
Company as part of the Anticipated Equity Financing, or any other agreement executed by the Company
in lieu of, and/or in addition to, the Anticipated Equity Financing, in each case, for purposes of
providing registration rights under the Act to holders of shares of Capital Stock, and the Company
shall ensure that any such agreement conforms with the requirements of this Section 3.4. Such
registration rights may not be amended, modified or waived without the prior written consent of the
Holder.




     4. Representations of Holder.



          4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is
acquiring the Warrant, the Exercise Shares and the shares of Common Stock issuable upon conversion
of the Exercise Shares (the “Underlying Shares”) solely for its account for investment and not with
a view to or for sale or distribution of said Warrant, Exercise Shares or Underlying Shares, or any
part thereof except in compliance with applicable federal and state securities laws. The Holder
also represents that the entire legal and beneficial interests of the Warrant, the Exercise Shares
and the Underlying Shares the Holder is acquiring is being acquired for, and will be held for, its
account only.




          4.2 Securities Are Not Registered.




               (a) The Holder understands that the Warrant, the Exercise Shares and the Underlying Shares
have not been registered under the Securities Act of 1933, as amended (the “Act”) on the basis that
no distribution or public offering of the stock of the Company is to be effected by the Holder. The
Holder realizes that the basis for the exemption may not be present if, notwithstanding its
representations, the Holder has a present intention of acquiring the securities for a fixed or
determinable period in the future, selling (in connection with a



 4.









 




distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention.




               (b) The Holder recognizes that the Warrant, the Exercise Shares and the Underlying Shares must
be held indefinitely unless they are subsequently registered under the Act or an exemption from
such registration is available; provided, however, the parties acknowledge and agree that the
Company has an obligation to register the Underlying Shares as provided in the Recapitalization
Agreement and the Convertible Preferred Stock Term Sheet.



               (c) The Holder is aware that neither the Warrant, the Exercise Shares nor the Underlying
Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met,
including, among other things, the existence of a public market for the shares, the availability of
certain current public information about the Company, the resale following the required holding
period under Rule 144 and the number of shares being sold during any three month period not
exceeding specified limitations.



          4.3 Disposition of Warrant, Exercise Shares and Underlying Shares.




               (a) The Holder further agrees not to make any disposition of all or any part of the Warrant,
the Exercise Shares or the Underlying Shares in any event unless and until:



                    (i) The Company shall have received a letter secured by the Holder from the Securities and
Exchange Commission stating that no action will be recommended to the Commission with respect to
the proposed disposition;



                    (ii) There is then in effect a registration statement under the Act covering such proposed
disposition and such disposition is made in accordance with said registration statement; or



                    (iii) The Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a detailed statement of the circumstances surrounding the proposed
disposition, and such disposition shall not be contrary to any applicable federal and/or state
securities laws.



               (b) The Holder understands and agrees that all certificates evidencing the shares to be issued
to the Holder may bear the following legend:




THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE
ACT OR UNLESS SUCH TRANSACTION IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE
SECURITIES LAWS.



          4.4 Accredited Investor Status. The Holder is an “accredited investor” as defined in
Regulation D promulgated under the Act.




 5.









 








     5. Adjustment of Exercise Price and Exercise Shares. 



          5.1 Changes in Securities. In the event of changes in the series of equity securities of the
Company comprising the Exercise Shares by reason of stock dividends, splits, recapitalizations,
reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations,
or the like, the number and class of Exercise Shares available under the Warrant in the aggregate
and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on
exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the
Holder would have owned had the Warrant been exercised prior to the event and had the Holder
continued to hold such shares until after the event requiring adjustment. For purposes of this
Section 5, the “Aggregate Exercise Price” shall mean the aggregate Exercise Price payable in
connection with the exercise in full of this Warrant. The form of this Warrant need not be changed
because of any adjustment in the number of Exercise Shares subject to this Warrant.




          5.2 Automatic Conversion. Upon the automatic conversion of all outstanding shares of the
series of equity securities comprising the Exercise Shares into Common Stock, if applicable, this
Warrant shall become exercisable for that number of shares of Common Stock of the Company into
which the Exercise Shares would then be convertible, so long as such shares, if this Warrant had
been exercised prior to such offering, would have been converted into shares of the Company’s
Common Stock pursuant to the Company’s Certificate of Incorporation. In such case, all references
to “Exercise Shares” shall mean shares of the Company’s Common Stock issuable upon exercise of this
Warrant, as appropriate.




          5.3 Dilutive Issuances. Notwithstanding any other provision of this Warrant or other
documents, if at any time prior to exercise of this Warrant, the Company issues or sells or is
deemed to have issued or sold additional shares of Capital Stock (including, without limitation in
the event that the nominal or effective price of Capital Stock is amended after initial issuance),
for a nominal or effective price less than the then effective Exercise Price (a “Dilutive
Issuance”), then and in each such case, as of the opening of business on the date of such issue or
sale, (or if later, the date on which the Exercise Price is determined in accordance with Section
2 hereof) the then existing Exercise Price shall be reduced to the price at which such shares are
issued or sold, or deemed to be issued or sold, and the number of Exercise Shares shall be
increased proportionately, so that after such adjustment the aggregate Exercise Price payable
hereunder for the increased number of Warrant Shares shall be the same as the aggregate Exercise
Price payable for the Warrant Shares immediately prior to such adjustment.. For purposes of this
Section 5.3, the Company will be deemed to have issued or sold additional shares of Capital Stock
if it issues any security or instrument convertible, exercisable or exchangeable for Capital Stock,
or if it promises, undertakes, commits, agrees or enters into any letter of intent to do so
(including by reducing the nominal or effective exercise price or nominal or effective conversion
price of a security exercisable, convertible or exchangeable for Capital Stock). Notwithstanding
the foregoing, (i) no further adjustment of the Exercise Price shall be made as a result of the
actual issuance of shares of Capital Stock upon the conversion, exercise or exchange of any such
instrument or in satisfaction of any such undertaking, commitment, agreement or letter of intent,
and (ii) no adjustment of the Exercise Price shall be made as a result of the actual issuance of
any shares of Common Stock pursuant to either (X) the exercise of those certain options to purchase
up to 35,000 shares of Common Stock at a purchase price of




 6.









 








$0.0001 per share that were outstanding on April 26, 2004 and held by members of the Board of
Directors of the Company; or (Y) the exercise of the Initial Bridge Warrants.




          5.4 Certificate of Adjustments. Upon each adjustment of the Exercise Price and/or Exercise
Shares, the Company shall promptly notify the Holder in writing and furnish the Holder with a
certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which
such adjustment is based.




     6. Fractional Shares. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) to be issued upon exercise of this Warrant shall be aggregated for purposes of
determining whether the exercise would result in the issuance of any fractional share. If, after
aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in
lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum
in cash equal to the product resulting from multiplying the then current fair market value of one
Exercise Share by such fraction.



     7. Transfer of Warrant. Subject to applicable laws, this Warrant and all rights
hereunder are transferable, in whole or in part, at any time or times by the Holder, upon delivery
of this Warrant and the form of assignment attached hereto to any transferee designated by Holder.
The transferee shall sign a customary investment letter in form and substance reasonably
satisfactory to the Company.



     8. Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or
destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company,
whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time
enforceable by anyone.



     9. Amendment. Any term of this Warrant may be amended or waived only with the written
consent of the Company and the Holder.



     10. Notices, etc. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given upon actual delivery to the recipient. All
communications shall be sent to the Company and to the Holder at the addresses listed on the
signature page hereof or at such other address as the Company or Holder may designate by ten (10)
days advance written notice to the other parties hereto.



     11. Governing Law. This Warrant and all rights, obligations and liabilities hereunder
shall be governed by and construed under the laws of the State of Delaware as applied to agreements
among Delaware residents, made and to be performed entirely within the State of Delaware without
giving effect to conflicts of laws principles.



[Signature Page Follows]





 7.









 









     In Witness Whereof, the Company has caused this Warrant to be executed by its duly
authorized officer as of the date first written above.



	 	 	 	 	 	 	 
	 	 	Northwest Biotherapeutics, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Name: Alton Boynton	 	 
	 
	 	 	 	 	 	 
	 	 	Title: President	 	 
	 
	 	 	 	 	 	 
	 

	 	Address:
	 	17801 120th Avenue NE	 	 
	 

	 	 	 	Suite 101	 	 
	 

	 	 	 	Bothell, WA 98011	 	 
	 

	 	 	 	Fax: (425) 608-3009	 	 






	 	 	 	 	 
	ACKNOWLEDGED AND AGREED:	 	 
	 
	 	 	 	 
	Toucan Partners, LLC	 	 
	 
	 	 	 	 
	By:

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Name: Linda Powers	 	 
	 
	 	 	 	 
	Title: Managing Member	 	 
	 
	 	 	 	 
	Address:

	 	7600 Wisconsin Avenue	 	 
	 

	 	Suite 700	 	 
	 

	 	Bethesda, MD 20814	 	 
	 

	 	Fax: (240) 497-4065	 	 






[Signature Page to Warrant No. BW-13]






 









 








NOTICE OF EXERCISE




TO: Northwest Biotherapeutics, Inc.




     (1) • •The undersigned hereby elects to purchase ___shares of ___(the
“Exercise Shares”) of Northwest Biotherapeutics, Inc. (the “Company”) pursuant to the
terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together
with all applicable transfer taxes, if any.



          • • The undersigned hereby elects to purchase ___shares of ___(the “Exercise
Shares”) of Northwest Biotherapeutics, Inc. (the “Company”) pursuant to the terms of the
net exercise provisions set forth in Section 2.1 of the attached Warrant, and shall tender payment
of all applicable transfer taxes, if any.




     (2) Please issue a certificate or certificates representing said Exercise Shares in the name
of the undersigned or in such other name as is specified below:



 





(Name)




 






 





(Address)




     (3) The undersigned represents that (i) the aforesaid Exercise Shares are being acquired for
the account of the undersigned for investment and not with a view to, or for resale in connection
with, the distribution thereof and that the undersigned has no present intention of distributing or
reselling such shares, except in accordance with applicable federal and state securities laws; (ii)
the undersigned is aware of the Company’s business affairs and financial condition and has acquired
sufficient information about the Company to reach an informed and knowledgeable decision regarding
its investment in the Company; (iii) the undersigned is experienced in making investments of this
type and has such knowledge and background in financial and business matters that the undersigned
is capable of evaluating the merits and risks of this investment and protecting the undersigned’s
own interests; (iv) the undersigned understands that Exercise Shares issuable upon exercise of this
Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), by reason of a specific exemption from the registration provisions of the Securities Act,
which exemption depends upon, among other things, the bona fide nature of the investment intent as
expressed herein, and, because such securities have not been registered under the Securities Act,
they must be held indefinitely unless subsequently registered under the Securities Act or an
exemption from such registration is available; (v) the undersigned is aware that the aforesaid
Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless
certain conditions are met and until the undersigned has held the shares for the number of years
prescribed by Rule 144, that among the conditions for use of the Rule is the availability of
current information to the public about the Company; and (vi) the undersigned agrees not to make
any disposition of all or any part of the aforesaid shares of Exercise Shares unless and until
there is then in effect a registration statement under the Securities Act covering such proposed
disposition or unless such transaction is in compliance with applicable federal and state
securities laws.



	 	 	 
	 

	 	 
	(Date)

	 	(Signature)
	 
	 	 
	 

	 	 
	 

	 	(Print name)






 1.









 








ASSIGNMENT FORM





(To assign the foregoing Warrant, execute this form
and supply required information. Do not use this
form to purchase shares.)



     For Value Received, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to



	 	 	 
	Name:
	 	 
	 

	 	 
	 

	 	(Please Print)






	 	 	 
	Address:
	 	 
	 

	 	 
	 

	 	(Please Print)






Dated: __________, 20__




	 	 	 
	Holder’s Signature:

	 	 
	 

	 	
 



 





	 	 	 
	Holder’s Address:

	 	 
	 

	 	
 



 




NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face
of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of
authority to assign the foregoing Warrant.





 2.









 





SCHEDULE 14.5

CONSENTS



None




 









 










SCHEDULE 14.6

CAPITALIZATION, FULLY DILUTED(1)




	 	 	 	 	 
	Common Stock as of 12/21/06 (per Mellon Investors Services)
	 	 	65,241,287	 
	Stock Options Outstanding as of 12/21/06
	 	 	773,510	 
	Warrants
	 	 	21,374,881	 
	 
	 	 	 	 
	Total fully diluted shares
	 	 	87,389,678	 








 




			
	(1)	 	Table excludes securities issued or issuable to Toucan.




 









 










SCHEDULE 14.8

LITIGATION



On February 3, 2006, Soma Partners, LLC filed another notice of appeal with the Supreme Court of
the State of New York. As of the date of this agreement, the Supreme Court of New York has yet to
act on this matter. On December 30, 2005,The Supreme Court of the State of New York dismissed
Soma’s petition, denying Soma’s August 29, 2005 motion to vacate the May 24, 2005 award in the
Company’s favor. The Company will continue to vigorously oppose such claims.



Two former members of the Company’s management, who participated as lenders in the Company’s
management loans have claimed that they are entitled to receive, for no additional cash
consideration, an aggregate of up to approximately 9.5 million additional shares of our common
stock due to the alleged triggering of an anti-dilution provision in the warrant agreements. The
Company does not believe that these claims have merit, and intends to vigorously oppose such
claims.




 









 










SCHEDULE 14.9

NO LIENS




     1. The Equipment Lessors listed below have security interests in equipment subject to their
respective leases (amounts due are as of March 27, 2007).



	 	 	 	 	 	 	 	 	 
	CAPITAL LEASES:	 	TOTAL AMOUNT	 	CAPITAL LEASES	 	AMOUNT DUE	 
	IOS Capital
	 	$21,789	 	Canon IR5000N	 	 	3,105	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	Total	 	$	3,105	 
	 
	 	 	 	 	 	 	 





     2. Pursuant to RCW 60.72.010, Maker’s landlord, Benaroya Capital Company, LLC,
under its premises lease has a statutory landlord lien. This is a statutory lien of general
application for all landlords and covers up to two months’ rent. This lien would be triggered upon
a default in payment of rent. Maker is not delinquent as to any rent due under its premises lease.
This lease is terminated, but Maker is seeking a final release letter.



     3. A $400,000 Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory Notes
dated November 14, 2005, a $250,000 Loan Agreement, Security Agreement and 10% Convertible, Secured
Promissory Notes dated December 30, 2005, as amended and a $300,000 Loan Agreement, Security
Agreement and 10% Convertible, Secured Promissory Notes dated March 9, 2006, as amended,
respectively; plus accrued interest thereon, and secured by a security interest in Maker’s assets
issued to Toucan.



     4. A License Agreement dated July 1, 2003 with Dako Cytomation for worldwide research and
diagnostic immunohistochemical (IHC) market. Hybridoma Cell Line, Monoclonal Antibody (MAb) to
Prostate Specific Membrane Antigen (PSMA), Clone IG3.



 









 






SCHEDULE 14.11

NO OTHER SECURITY INTERESTS OR ENCUMBRANCES



1. (a) The Equipment Lessors listed below have security interests in equipment subject to their
respective leases (amounts due are as of March 27, 2007).




	 	 	 	 	 	 	 	 	 
	CAPITAL LEASES:	 	TOTAL AMOUNT	 	CAPITAL LEASES	 	AMOUNT DUE	 
	IOS Capital
	 	$21,789	 	Canon IR5000N	 	 	3,105	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	Total	 	$	3,105	 
	 
	 	 	 	 	 	 	 





          (b) A License Agreement dated July 1, 2003 with Dako Cytomation for
worldwide research and diagnostic immunohistochemical (IHC) market. Hybridoma Cell Line, Monoclonal
Antibody (MAb) to Prostate Specific Membrane Antigen (PSMA), Clone IG3.




     2. Pursuant to RCW 60.72.010, Maker’s landlord, Benaroya Capital Company, LLC, under its
premises lease has a statutory landlord lien. This is a statutory lien of general application for
all landlords and covers up to two months’ rent. This lien would be triggered upon a default in
payment of rent. Maker is not delinquent as to any rent due under its premises lease.



     3. This lease is terminated, but Maker is seeking a final release letter.



     4. A $400,000 Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory Notes
dated November 14, 2005, a $250,000 Loan Agreement, Security Agreement and 10% Secured Promissory
Notes dated December 30, 2005, as amended and a $300,000 Loan Agreement, Security Agreement and 10%
Secured Promissory Notes dated March 9, 2006, as restated and amended, respectively; plus accrued
interest thereon, and secured by a security interest in Maker’s assets issued to Toucan.


* All the holders of the 10% Convertible Secured Notes are parties to a Subordination Agreement
with Toucan executed concurrent with the            Recapitalization Agreement.




 









 








SCHEDULE 14.14(A)

SEC FILINGS



1. Maker did not file on a timely basis its annual report on Form 10-K with the SEC for its fiscal
years ended December 31, 2003 and 2005.




 









 








SCHEDULE 14.15

LIABILITIES



As of March 27, 2007, Maker has the following accrued liabilities: (i) amounts payable to Cognate
Therapeutics and Investor, (ii) Maker’s aggregate accrued, contingent and/or other liabilities of
any nature, either mature or immature, as of the date hereof, not in excess of $1,000,000
(excluding amounts payable to Cognate and Investor), of which (a) approximately $388,000 are
currently due payables (including, without limitation, approximately $128,000 for attorney fees),
(b) $1,500 are the aggregate balances of capital leases payable in monthly installments the last of
which is to be paid in May 2007, (c) $175,000 represents estimated accruals for payables to
European consultants, (d) $110,000 represents estimated accruals for payables related to clinical
trials, (e) $190,000 represents estimated other accounts payable and accruals for SEC filings and
other, (e) $35,000 are accrued payroll and (f) $100,000 are accrued vacation and sick pay.




 









 








EXHIBIT C




Form of Warrant